A tonsillar polyICLC/At-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessation
Background: HIV-infected individuals rely on antiretroviral therapy (ART) to control viral replication. Despite abundant demonstrable benefits, the multiple limitations of ART point to the potential advantages of therapeutic vaccination approaches that could provide sustained host control of viral replication after discontinuation of ART. We provide evidence from a non-human primate model that a therapeutic vaccine applied to the tonsils can maintain low viral loads after cessation of ART. Methodology/Principal Findings: Animals received 40 weeks of ART initiated 9 weeks after rectal SIVmac239 infection. During ART, animals were vaccinated (or not) with AT-2 inactivated SIVmac239 using CpG-C ISS-ODN (C274) or polyICLC as adjuvants. PolyICLC/AT-2 SIV vaccinated animals maintained viral loads <3×103 copies/ml for up to 16 weeks post-ART, whereas the C274/AT-2 SIV vaccinated and non-vaccinated animals' viremia ranged between 1×104-4×105 copies/ml (p
Vagenas, Panagiotis, Meropi Aravantinou, Vennansha G. Williams, Edith Jasny, Michael Piatak Jr., Jeffrey D. Lifson, Andres M. Salazar, James Blanchard, Agegnehu Gettie, and Melissa Robbiani. 2010. "A tonsillar polyICLC/AT-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessation," PLoS ONE 5(9): e12891.